Beckman Coulter Life Sciences has unveiled the Cydem VT Automated Clone Screening System, a cutting-edge solution for lab managers seeking to streamline cell line development workflows. By automating up to 90 percent of manual steps, this advanced system enables faster, more reliable clone selection for monoclonal antibody (mAb) therapeutics and biologic drug discovery.
Designed for cultivating CHO cell lines, the platform integrates multiple Beckman Coulter technologies to provide labs with early insights into cell growth and productivity. Automated operations deliver at least three days of walk-away time, freeing up staff resources while improving overall accuracy.
Benefits for lab managers:
- Time-Saving Automation: Eliminates most manual steps, reducing labor-intensive processes.
- High Throughput: Screens up to 96 clones simultaneously under fed-batch conditions.
- Consistent Results: Integrated tools for pH, dissolved oxygen, and titer concentration monitoring.
- User-Friendly Design: Streamlined workflows ensure accessibility for labs of varying expertise levels.
- Improved Accuracy: Reduces the risk of selecting poor productivity clones, ensuring better outcomes.
“Our Cydem VT Automated Clone Screening System offers an exciting revolution to expedite critical research therapies for illnesses, including autoimmune diseases and many types of cancer,” said Dr. Sebastian Hofzumahaus, Product Manager at Beckman Coulter.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: "Beckman Coulter Life Sciences Accelerates Drug Discovery with Launch of Cydem VT Automated Clone Screening System."
